Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option

Abstract

Purpose Advances in the management of severe, eosinophilic asthma have improved, but asthma exacerbations continue to occur. This review aims to look at the evidence we have about why exacerbations may occur; their phenotype and why oral corticosteroids may not always be the best treatment option for all exacerbation of symptoms in individuals with severe asthma. Recent findings Studies dating back to the 1990s showed that asthma exacerbations across the spectrum of asthma severity were of different inflammatory endotypes. In addition, there is a wealth of evidence suggesting that eosinophilic inflammation is very responsive to corticosteroid therapy, but that non-eosinophilic inflammation is less so. Two recent UK-based studies have undertaken systematic phenotyping of exacerbations in severe asthma and have shown that there are a significant minority of exacerbation events with an increase in asthma symptoms, fall in lung function, but without evidence of raised T2 biomarkers. Summary The evidence to date would suggest that T2 biomarker low asthma exacerbations do not benefit from the administration of oral corticosteroids; in fact, the effect of the oral corticosteroids is harmful. However, there is a paucity of data to answer this question directly. Further research is needed to assess the evolution of non-T2 exacerbations not treated with OCS in a randomised, placebo-controlled, manner.

Advances in the Relationship between Respiratory Viruses and Asthma

“…The use of ICS as maintenance therapy that is fundamental in asthma treatment is effective in reducing the risk of future asthma exacerbations caused by the virus, along with decreasing the risk due to the use of long-acting β-2 agonists [1]. Cochrane Database review signals that is implausible for a reduction in the need for oral steroids if the dosage increases in adults and children with mild to moderate asthma in the presence of the first couple of clinical manifestations of an exacerbation [94]. Several studies have proven that asthma exacerbations have different spectrums according to inflammatory endotypes.…”